...
首页> 外文期刊>European spine journal: official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society >Evaluation of an increased strut porosity silicate-substituted calcium phosphate, SiCaPEP, as a synthetic bone graft substitute in spinal fusion surgery: a prospective, open-label study
【24h】

Evaluation of an increased strut porosity silicate-substituted calcium phosphate, SiCaPEP, as a synthetic bone graft substitute in spinal fusion surgery: a prospective, open-label study

机译:评价由脊柱融合手术的合成骨移植替代品增加的支撑孔隙硅酸盐硅酸盐磷酸钙磷酸钙,作为脊柱融合手术的合成骨移植替代品:一项前瞻性开放标签研究

获取原文
获取原文并翻译 | 示例
           

摘要

PurposeSilicate-substituted calcium phosphate-enhanced porosity (SiCaP EP, Inductigraft (TM), Altapore) is a synthetic bone graft material with enhanced strut porosity of 31-47%. SiCaP EP remains to be fully clinically evaluated in patients undergoing instrumented posterolateral fusion (PLF) surgery. We conducted a prospective, open-label, non-randomised, multicentre clinical study to evaluate efficacy of SiCaP EP as bone grafting material in PLF surgery with instrumentation for treatment of spinal disorders.MethodsPatients with degenerative disc disease, spondylolisthesis or spinal stenosis underwent PLF surgery with SiCaP EP. The primary endpoint was evaluated in the per protocol population (N=102) as solid fusion at postoperative month 12 assessed using computed tomography scans, with motion assessed using flexion-extension radiographs. Clinical outcomes included the Oswestry Disability Index, 36-item short-form health survey for quality-of-life, visual analog scale for pain scores and neurological assessments. Adverse events were recorded.ResultsSuccessful fusion was achieved in 59/89 (66.3%) patients at month 6, 88/102 patients (86.3%) at month 12 (primary endpoint) and 87/96 (90.6%) patients at month 24. Disability and pain reduced following surgery. Quality-of-life improved and neurological function was maintained postoperatively. Forty-three (33.3%) of the 129 patients who underwent surgery experienced adverse events; back pain was most frequent (n=10); nine and 14 patients experienced serious adverse events judged related to device and procedure, respectively.ConclusionsEnhanced strut porosity SiCaP EP provided high (month 12: 86.3%) spinal fusion success rates in PLF surgery. Fusion success was associated with improved clinical outcomes in patients within 12months, relative to baseline.ClinicalTrials.gov identifierNCT01452022Graphical abstractThese slides can be retrieved under Electronic Supplementary Material.
机译:初始硅酸盐取代的磷酸钙增强孔隙率(SiCAP EP,Incuctigraff(TM),Altapore)是一种合成骨接枝材料,增强的支柱孔隙率为31-47%。 SICAP EP仍然是在接受仪表后的后侧融合(PLF)手术的患者中进行全临床评估。我们进行了一项前瞻性,开放标签,非随机化的多期临床研究,以评估SiCAP EP作为PLF手术中的骨移植材料的疗效,用于治疗脊髓紊乱。用退行性椎间盘疾病的方法,脊椎细胞间或脊柱狭窄接受PLF手术用sicap ep。作为使用计算机断层扫描评估的术后月12的固体融合,在每种方案群体(n = 102)中评估初级终点,用屈曲 - 扩展射线照片评估的运动。临床结果包括肌醇残疾指数,36项短态健康调查,用于寿命质量,视觉模拟规模用于疼痛评分和神经系统评估。记录不良事件。在第12月6日(主要终点)和87/96(90.6%)患者的59/89名(66.3%)患者中,在59/89名(66.3%)和87/96(90.6%)患者月24日患者中达到不良事件。手术后残疾和疼痛减少。术后维持寿命质量改善和神经功能。 49名接受手术的129名患者的四十三(33.3%)经历不良事件;背部疼痛最常见(n = 10);九个和14名患者经历了与装置和程序相关的严重不良事件。ConclusionsenHanced支撑孔隙度SiCAP EP提供高(月12:86.3%)PLF手术中的脊髓融合成功率。融合成功与12个月内的患者的改善临床结果有关,相对于基线.ClinicTrials.gov标识符NCT01452022可以在电子补充材料下检索载玻片。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号